| Molecular Formula | C15H11ClF3N5O4S |
| Molar Mass | 449.79 |
| Melting Point | >166°C (dec.) |
| Solubility | DMSO: soluble15mg/mL, clear |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | Keep in dark place,Sealed in dry,2-8°C |
| In vitro study | The compounds of the Kobe0065 family bind to Ras-GTP and have anti-proliferative activity against cancer cells carrying an activated ras oncogene. It effectively inhibits the interaction of Ras ~ GTP with its effector proteins such as Raf, PI3K, RalGDS and the regulator/effector Sos, with a broad binding specificity for various small GTPases of the Ras family. |
| In vivo study | Kobe0065 has anti-tumor activity. Tumors treated with this compound significantly increased their apoptotic cells without significant weight loss. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | 22 - Harmful if swallowed |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.223 ml | 11.116 ml | 22.233 ml |
| 5 mM | 0.445 ml | 2.223 ml | 4.447 ml |
| 10 mM | 0.222 ml | 1.112 ml | 2.223 ml |
| 5 mM | 0.044 ml | 0.222 ml | 0.445 ml |
| biological activity | Kobe0065 is an inhibitor of H-Ras-cRaf1 interaction and can effectively inhibit the combination of H-Ras · GTP and c-Raf-1 RBD with a Ki value of 46±13 μM. |
| target | TargetValue H-Ras-cRaf1 interaction () |
| Target | Value |
| in vitro study | Kobe0065 family compounds bind to Rasevents and have anti-proliferative activity against cancer cells carrying the ras-activated oncogene. It effectively inhibits the interaction of RasaS GTP with its effector proteins such as Raf, PI3K, RalGDS and regulatory/effector Sos, and has a wide range of binding specificity for small GTP enzymes of various Ras families. |
| in vivo research | Kobe0065 have anti-tumor activity. Tumors treated with this compound significantly increased their apoptotic cells without significant weight loss. |